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all 3 studies were analysed using latent growth models to generate intercepts and 
slopes of change across trials for each patient, irrespective of treatment. Slopes 
of change were correlated to examine how closely DLQI changes mirrored UAS7 
changes. Results: Results indicated that both measures showed large improve-
ments over the course of the trials: UAS7 and DLQI scores were high at the start 
of the study reflecting moderate-severe CSU/CIU (UAS7) and a very large effect on 
patient’s life (DLQI). Correlations between changes in DLQI and changes in UAS7 by 
study end were 0.88, 0.85, and 0.88, indicating high correspondence between the two 
measures. ConClusions: These results suggest that collecting DLQI information 
in-clinic can provide an excellent indication of the weekly UAS7 score, and is more 
efficient for clinical practice routine in assessing CSU/CIU patients.
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objeCtives: Some psoriasis patients also have psoriatic arthritis (PsA), which 
increases disease burden and further reduces quality-of-life (QoL). Our objective 
was to compare QoL of subjects with both psoriasis and PsA to those with psoriasis 
alone, and to evaluate improvement on etanercept (ETN) therapy in specific coun-
tries of Central and Eastern Europe, Latin America, and Asia where data are lim-
ited. Methods: Patients with moderate/severe psoriasis were randomized to 50mg 
ETN QW (once weekly) or 50mg ETN BIW (twice weekly, weeks 1-12), followed by 50mg 
QW (weeks 13-24). The following post-hoc assessments were included: EuroQoL-5D 
(EQ-5D); Dermatology Quality of Life Index (DLQI); Functional Assessment of Chronic 
Illness Therapy (FACIT)-Fatigue; Hospital Anxiety and Depression Scale (HADS); 
Medical Outcomes Study (MOS)-Sleep; and Work Productivity and Activity Impairment 
(WPAI). Subjects with and without PsA were pooled across ETN groups for compari-
sons of changes in scores from baseline to week 24, which were based on independent 
sample t-tests. Results: Of 171 subjects analysed, 64 (37.4%) had PsA. Baseline demo-
graphic characteristics and QoL measures were similar in PsA and psoriasis-alone 
groups. EQ-5D scores improved significantly over time with ETN treatment in both 
subjects with and without PsA (P< 0.0001) with similar adjusted mean improvement 
in both groups after 24 weeks (0.2 vs 0.2; P= 0.6202). Improvement in EQ-5D greater 
than MID (change ≥ 0.05) at week 24 was observed in a greater proportion of PsA than 
psoriasis-alone subjects (74.6% vs 63.8%; P= 0.174). Significant improvements from 
baseline in both PsA and psoriasis-alone groups were also observed after 24 weeks in 
DLQI (both P< 0.0001), FACIT (both P< 0.01) and HADS anxiety (both P< 0.0001) scores. 
Improvements of other patient-reported outcomes were also observed at weeks 24 in 
both disease subgroups. ConClusions: ETN in both dose regimens provided signifi-
cant improvement in QoL measures in subjects with moderate-to-severe psoriasis, 
regardless of the presence of PsA.
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objeCtives: To assess the impact of etanercept (ETN) on quality-of-life (QoL) through 
24 weeks in patients with moderate/severe psoriasis in specific countries of Central 
and Eastern Europe, Latin America, and Asia where data are limited. Methods: 
Patients with moderate/severe psoriasis were randomized to 50mg ETN QW (once 
weekly) or 50mg ETN BIW (twice weekly, weeks 1-12), followed by 50mg QW (weeks 
13-24). Patients completed the Dermatology Life Quality Index (DLQI) EuroQoL 5D (EQ-
5D), FACT-Fatigue, HADS Anxiety Score, Psoriasis Subject Satisfaction Questionnaire, 
and Work Productivity Activity Impairment (WPAI) at baseline and subsequent vis-
its. Results: Of 171 patients analysed, 85 were randomised to ETN BIW and 86 to ETN 
50 QW. Baseline DLQI scores were 14.8 in both treatment groups suggesting severe 
QoL impairment. Significant improvements in DLQI from baseline were observed 
at weeks 12 and 24 in both groups (all p< 0.0001); mean improvement at week 12 for 
ETN BIW was greater than for ETN QW (10.8 vs 8.4, p= 0.001), but was similar between 
groups at week 24 (11.0 vs 9.5, p= 0.063). EQ-5D utility was significantly improved 
from baseline in both groups at weeks 12 and 24 (all p< 0.0001), with mean improve-
ment significantly greater for the higher dose at both time-points (week 12: 0.3 vs. 
0.2, p= 0.029; week 24: 0.3 vs. 0.2, p= 0.027). Mean EQ-5D improvement at week 24 
was greater than MID (change ≥ 0.05) in a significantly greater proportion of patients 
receiving BIW than QW (77.1% vs 58.8%; p= 0.013). Improvements of other patient-
reported outcomes from baseline were observed at weeks 12 and 24 in both treat-
ment groups. ConClusions: At baseline, patients had severely impaired QoL, and 
improvement in QoL was achieved with both ETN regimens. Improvements observed 
with ETN BIW were significantly greater than with ETN QW for both DLQI and EQ-5D 
utility at week 12, but only for EQ-5D at week 24.
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used, thus confirming external validity. The mean score calculated from the ABS 
is 48.17±18.36. The score increases with the severity of the AD. A statistically sig-
nificant difference is observed between the 3 severity-groups, i.e. mild, moderate 
and severe, with scores of 30.63, 42.55 and 62.62 respectively. ConClusions: The 
internal and external validity of our Q were confirmed. ABS is correlated with the 
severity of AD. Hence, we have a short, easy-to-use, validated tool for assessing the 
burden imposed by atopy on families. Following cultural and linguistic validation, 
the ABS is now available in US English, Spanish, German and Italian.
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objeCtives: The notion of individual burden, associated with the disease, has 
been introduced recently to determine the “disability” caused by the pathology in 
the broadest sense of the word (psychological-social-economic-physical). The aim 
of our study is to develop a specific questionnaire for assessing the burden on fami-
lies of children with HI. Methods: A “Hemangioma Family Burden” questionnaire 
(HFB) consisting of 22 items, The score increases with the heaviness of the burden. It 
was distributed accompanied by 2 validated QoL questionnaires (SF12 and PGWBI) 
to obtain internal and external validation Results: A total of 58 evaluable Q were 
returned. One parent from each family described how they perceived the effects of 
the disease, which led to the creation of 6 severity groups, paired together for size 
reasons: “not-very-far-reaching” and “somew-hat-far-reaching”; “quite-far-reaching” 
and “far-reaching”; “very far-reaching” and “extremely far-reaching”. Internal validity 
was measured by Cronbach’s alpha, which is equal to 0.95, reflecting a good homoge-
neity of the 22 Q items. The mean scores of the physical and mental components are 
54.93±5.12 and 40.49±11.28 respectively. Hence, the HFB score is correlated with these 
2 components, thus confirming external validity. The mean score calculated from the 
HFB is 23.42±19.93. The score increases with the “severity score” of the parents. In 
fact, a statistically significant difference is observed between the 3 severity groups: 
5.28±6.8 for those reporting the smallest extent to 41.0±18.71 for those reporting the 
greatest extent, and 27.7±16.96 for a moderate extent. This confirms the sensitivity of 
the HFB ConClusions: During the evaluation, internal and external validity were 
confirmed. The HFB is correlated with the extent felt by parents, a feeling deemed 
relevant because it is often the cause of consultation and demand for treatment. 
We now have an easy-to-use, validated IH tool for assessing the disability caused. 
Following cultural and linguistic validation, the HFB is now available in US English, 
Spanish, German and Italian.
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objeCtives: Patient reported outcomes (PRO) are becoming useful tools for 
collecting and generating evidence for new medical products to show improve-
ments in health-related quality of life (HRQoL). Glaucoma is a chronic disease 
with high importance for patient HRQoL. The objective of this study was to review, 
analyze, and understand trends in the PRO instruments used in patients with 
Glaucoma. Methods: A systematic literature search for Glaucoma trials with 
PROs endpoints was undertaken for the databases Pubmed, Embase, Biosis, Google 
Scholar and Cochrane. Data was collected for the study size, interventions, year, 
PRO instrument and results for PROs. Analysis for conducted to identify trends 
in commonly used PRO instruments and categorize results as positive, neutral or 
negative. Results: A total of 31 studies with a total of 9819 patients were identi-
fied. In these studies there were eleven different PROs instruments were identified 
that were Glaucoma health perception index, Glaucoma quality of life question-
naire (Glau-QoL), Glaucoma utility index, Impact of vision impairment, Low vision 
quality of life questionnaire, National eye institute visual function index-19 items, 
National eye institute visual function index-51 items, Nursing home vision quality 
of life questionnaire, Quality of life and visual function questionnaire, Vision core 
module 1, and Vision quality of life index. The most commonly used instruments 
were Impact of vision impairment (used in 7 studies) and Low vision quality of life 
questionnaire (used in 4 studies). ConClusions: Patients with glaucoma have 
significant impairment in their QoL, hence collection of such data is important 
for new medical products. PRO instruments such as Impact of vision impairment 
and Low vision quality of life questionnaire have been commonly used to generate 
evidence to show which therapies improve patient QoL.
PSS43
corrElationS bEtwEEn changES in thE urticaria activity ScorE 
(uaS7) and thE dErmatology lifE Quality indEx (dlQi) from baSElinE 
to 28 or 40 wEEkS: comPariSonS of trajEctoriES of changE in PatiEntS 
with chronic SPontanEouS/idioPathic urticaria (cSu/ciu)
Stull D.E.1, McBride D.2, Balp M.M.3, Gnanasakthy A.4
1RTI Health Solutions, Didsbury, Manchester, UK, 2RTI Health Solutions, Manchester, UK, 
3Novartis Pharma AG, Basel, Switzerland, 4Novartis Pharmaceuticals, East Hanover, NJ, USA
objeCtives: The UAS7 is a patient-reported measure of urticaria symptoms. Daily 
pruritus scores and number of hives are summed over 7 days for a weekly score. The 
DLQI was developed as a brief (10-item) patient-reported measure with one-week 
recall for routine clinical use to assess the psychosocial effects of skin disease. The 
objective of this analysis was to examine changes in the UAS7 with those of the 
DLQI to see if the DLQI could be used in a clinic visit in lieu of collecting one week 
of UAS7 diary data. Methods: Data come from three pivotal, phase 3 clinical tri-
als investigating the effects of omalizumab for patients with refractory CSU/CIU 
(publication available elsewhere). DLQI data were collected at baseline and weeks 
4, 12, 24, and 40 (ASTERIA I and GLACIAL), and baseline and weeks 4, 12, and 28 
(ASTERIA II). UAS7 score was reported at baseline and every four weeks but data 
from the same weeks as the DLQI were used for these analyses. Pooled data from 
